Our leaders are industry professionals with extensive experience in discovery, development, and commercialization. We complement our management team with a group of scientific and medical advisors that includes recognized experts in the fields of schizophrenia and other central nervous system disorders.
Dr. Mates has been the Chairman of the board of directors, President and Chief Executive Officer of ITI since June 2002. Dr. Mates co-founded ITI in May 2002. Prior to co-founding ITI, Dr. Mates was a co-founder of Functional Genetics, and served as its Chairman and Chief Executive Officer from December 2000 until August 2003. From 1989-1998, Dr. Mates was the President and a board member of North American Vaccine Inc. and its predecessor companies. She has served on several boards, and recently completed a board membership and a two-year chairmanship of the Board of the New York Biotechnology Association. Dr. Mates has also served on the Advisory Council of the Center for Society and Health at the Harvard School of Public Health, the Board of Visitors of the Biotechnology Institute of the University of Maryland, and the board of directors of Gilda's Club of New York. Earlier in her career, Dr. Mates spent several years as a research analyst and investment banker, and as an advisor to the life sciences industry. Dr. Mates received her B.S. from the Ohio State University and her Ph.D. from the University of Washington, and completed her postdoctoral fellowships at The Massachusetts General Hospital and Harvard Medical School.
Dr. Satlin joined the Company as Executive Vice President and Chief Medical Officer in November 2017. Dr. Satlin has over 20 years of industry experience in all phases of drug development in multiple therapeutic areas, including neurology and psychiatry, as well as cardiovascular and metabolic disorders. Prior to joining Intra-Cellular Therapies, Dr. Satlin spent 9 years at Eisai, most recently serving as Executive Vice-President, Global Head of Medicine Creation Strategy, Neurology Business Group. Before joining Eisai, he spent 11 years at Novartis in positions of increasing responsibility, including leadership of the Neurosciences regulatory group. Prior to joining Novartis Dr. Satlin was an Assistant Professor of Psychiatry at Harvard Medical School. Dr. Satlin was also the Director of Geriatric Psychiatry and established a dementia clinic at McLean Hospital in Massachusetts. Dr. Satlin received his medical degree from Harvard Medical School and completed his residency in psychiatry and fellowship in geriatric psychiatry at McLean Hospital. Dr. Satlin received his bachelor's degree from Yale University.
Mr. Neumann joined the Company as Executive Vice President and Chief Commercial Officer in October 2018. Mr. Neumann has over 30 years of biopharmaceutical industry experience with a strong track record of building high-performing commercial teams and successfully executing numerous product launches across a range of therapeutic areas. Mark joins ITCI from Amgen where he was initially recruited as Vice President, Marketing to build and establish a new U.S. cardiovascular business unit, and launch Amgen’s first ever cardiovascular medicines. In his most recent role as Vice President, Global Marketing with leadership of nephrology, inflammation, and bone health, Mr. Neumann was responsible for conceiving therapeutic area strategies, developing marketing platforms for global launches and directing commercial assessments for external business development opportunities. Prior to Amgen, Mr. Neumann spent 25 years at Bristol-Myers Squibb (BMS) and held senior U.S. and global commercial roles in neuroscience, cardiovascular and diabetes. During his tenure at BMS he led sales and marketing for the U.S. neuroscience business unit, and delivered strong growth of the antipsychotic Abilify. He also held the position of Vice President, Global Commercialization for neuroscience where he established a new worldwide disease area strategy and directed the commercialization of neuroscience pipeline assets. Mark received his Bachelor of Arts in Economics and Business Administration degree from Lafayette College.
Mr. Halstead has been the Senior Vice President, General Counsel of ITI since July 2014. From July 2005 until December 2013, Mr. Halstead served in a number of leadership positions at Warner Chilcott plc, a leading specialty pharmaceutical company that was acquired by Actavis plc in October 2013. Most recently, he was Senior Vice President, Corporate Development at Warner Chilcott, where he directed the company’s corporate development, legal, and human resources functions. Prior to that, Mr. Halstead was an attorney at Davis Polk & Wardwell, where he focused his practice on mergers and acquisitions, corporate governance, and securities law compliance. Mr. Halstead received his bachelor's degree from Boston University and his Juris Doctor degree from Villanova University School of Law.
Mr. Hineline has served as Vice President of Finance, Chief Financial Officer, and Secretary of ITI since June 2002. From December 2000 to November 2003, Mr. Hineline was the Vice-President of Finance and Chief Financial Officer of Functional Genetics, Inc. Prior to that, Mr. Hineline served as the Vice President of Finance of North American Vaccine, Inc. and its predecessor companies from 1993 to 2000, and as Corporate Controller from 1989 to 1993. During this time, Mr. Hineline oversaw the growth of the accounting function and its systems for the company that emerged as a start-up and was later acquired by Baxter Health Care. Mr. Hineline is a licensed CPA in the State of Maryland and received his Bachelor's Degree from the University of Maryland Baltimore County.
Dr. Durgam joined the Company as Senior Vice President, Late Stage Clinical Development and Medical Affairs in August 2018. Dr. Durgam, brings over 15 years of experience in neuropsychiatric drug development, including the development of antipsychotics and antidepressants. Suresh served in clinical development leadership roles at Allergan plc where he was the clinical lead responsible for development of treatments for mood disorders including ripastinel, and other rapid-acting antidepressant programs. Dr. Durgam was also the clinical development lead of the antipsychotic, cariprazine, advancing the compound from Phase I to approval in schizophrenia and bipolar disorder. Dr. Durgam graduated with his medical degree from the Siddhartha Medical College in India and received his residency training in psychiatry at Scott & White Clinic and Hospital - Texas A&M University System College of Medicine.
Dr. Vanover joined the Company in March 2007 and has been Senior Vice President, Clinical Development of the Company since November 2015. Previously, she held various positions since joining in 2007, and has spent over 20 years on the discovery and development of small molecule drugs for the treatment of neuropsychiatric and neurodegenerative diseases, including work in the areas of schizophrenia, bipolar disorder, and dementia. Dr. Vanover was a Postdoctoral Research Scientist at Lederle Laboratories from 1992 to 1994, Postdoctoral Research Trainee in the Department of Psychiatry at the University of California, San Diego from 1994 to 1995, Senior Scientist and Group Leader at CoCensys from 1995 to 2000, and has held various positions as Group Leader and Director at ACADIA Pharmaceuticals from 2000 to 2007. In these positions, Dr. Vanover participated in the discovery and development of a broad range of new CNS therapeutics, including drugs to treat psychosis, insomnia, cognitive impairment, movement disorders, acute and neuropathic pain, anxiety, epilepsy, and drug abuse. She has also participated in the discovery and development of Nuplazid, the first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Dr. Vanover received her B.A. in Psychology from the University of Missouri and her Ph.D. in Biopsychology from the University of Chicago.
Dr. Davis has served as Senior Vice President, Chief Scientific Officer since November 2015. Previously, Dr. Davis served as President and CEO of 3-D Pharmaceutical Consultants, providing consulting services to the Company from December 2005 to November 2015. From December 2000 until November 2005, Dr. Davis served as the Executive Vice President, Research and Development at ACADIA Pharmaceuticals. From January 1994 until October 2000, Dr. Davis held various positions at MitoKor, a development stage biotechnology company focused on the design and development of drug therapies for mitochondrial diseases, serving at various times as its President, Chief Executive Officer, and Chief Scientific Officer. Earlier, Dr. Davis held various positions at Parke-Davis Pharmaceutical Research, Warner-Lambert. Earlier in his career, he participated in the discovery and development of Cognex, the first drug approved for treating Alzheimer’s disease; Neurontin, the first drug approved for treating neuropathic pain; and Nuplazid, the first drug approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Dr. Davis received his B.S., M.S., and Ph.D. in Psychobiology from the University of Illinois.
Dr. Olchaskey joined the Company as Senior Vice President, Head of Regulatory Affairs in September 2018. Dr. Olchaskey has over 20 years of global regulatory affairs experience with investigational and commercialized products across a range of CNS disorders, including schizophrenia, bipolar disorder, depression, Alzheimer's disease, and Parkinson's disease. Michael has held positions of increasing responsibility and scope in Regulatory Affairs at Allergan plc over the last 16 years. He has overseen a wide array of submissions and approvals for products, including cariprazine, asenapine, escitalopram, levomilnacipran, milnacipran, and vilazodone. Dr. Olchaskey received his Bachelor of Science in Pharmacy and Doctor of Pharmacy degree from Rutgers University. He also did a Post-Doctoral Fellowship jointly sponsored by Hoffmann La Roche and Rutgers University.
Dr. Sanchez has been the Vice President of Corporate Communications and Investor Relations since March 2014. He has over ten years of experience as a Wall Street research analyst with a deep focus on companies specializing in CNS diseases. From 2008 to 2014, he served in the roles of Managing Director and Vice President of Healthcare Equity Research at Ladenburg Thalmann & Co. Prior to joining Ladenburg Thalmann & Co. Dr. Sanchez was a Vice President of Equity Research at Punk Ziegel. Before joining Wall Street, Dr. Sanchez received a Master of International Affairs degree from Columbia University in New York and an MBA from University of Los Andes in Bogota, Colombia. Dr. Sanchez practiced medicine for five years in his native country, Colombia, having received a medical degree from Pontifical Xavierian University.